1. Nanomedicine potentiates mild photothermal therapy for tumor ablation
- Author
-
Yang Ding, Feng Zhang, Zijun Jiang, Hao Cheng, Jianping Zhou, Tianyi Li, Shihao Wang, and Xiaoyu Yang
- Subjects
Pharmacology ,Antitumor immunity ,Mild temperature PTT ,business.industry ,Thermo-resistance ,Autophagy ,Normal tissue ,Promote mPTT monotherapy ,Pharmaceutical Science ,RM1-950 ,Review ,Photothermal therapy ,Tumor ablation ,Nanomedicine ,Cancer cell ,Synergistic therapy ,Cancer research ,Medicine ,Therapeutics. Pharmacology ,Heat shock ,business - Abstract
The booming photothermal therapy (PTT) has achieved great progress in non-invasive oncotherapy, and paves a novel way for clinical oncotherapy. Of note, mild temperature PTT (mPTT) of 42–45 °C could avoid treatment bottleneck of the traditional PTT, including nonspecific injury to normal tissues, vasculature and host antitumor immunity. However, cancer cells can resist mPTT via heat shock response and autophagy, thus leading to insufficient mPTT monotherapy to ablate tumor. To overcome the deficient antitumor efficacy caused by thermo-resistance of cancer cells and mono mPTT, synergistic therapies towards cancer cells have been conducted with mPTT. This review summarizes the recent advances in nanomedicine-potentiated mPTT for cancer treatment, including strategies for enhanced single-mode mPTT and mPTT plus synergistic therapies. Moreover, challenges and prospects for clinical translation of nanomedicine-potentiated mPTT are discussed., Graphical Abstract Graphical Abstract Image, graphical abstract
- Published
- 2021